Medical PCBA by Surface Art Request a quote

FDA QMSRRegulation

FDA QMSR: what it means for your PCBA supplier

Short answer

FDA's Quality Management System Regulation (QMSR) is the amended 21 CFR Part 820. It took effect on February 2, 2026 and incorporates ISO 13485:2016 by reference. It applies to manufacturers of finished devices; 21 CFR 820.1(a)(2) says it does not apply to manufacturers of components or parts, who are encouraged to consider it. For a PCBA supplier, its requirements arrive through the device maker's purchasing controls and quality agreement.

What is the FDA QMSR?

The QMSR is FDA's current good manufacturing practice (CGMP) rule for medical devices: 21 CFR Part 820, now titled the Quality Management System Regulation. FDA amended Part 820 in a final rule published on February 2, 2024 (89 FR 7496) and corrected in October 2024 (89 FR 82945). The amended rule incorporates ISO 13485:2016 by reference, with Clause 3 of ISO 9000:2015 for definitions, and replaces most of the Quality System (QS) regulation FDA established in 1996.

Part 820 now has three working parts:

  • The core requirement to document a quality management system that complies with ISO 13485 (§ 820.10).
  • FDA additions, such as UDI, complaint and servicing records, and labeling and packaging controls (§§ 820.10, 820.35, 820.45).
  • A conflict rule: where an ISO 13485 clause conflicts with the FD&C Act or FDA's regulations, the US requirements control (§ 820.1(b)).

When did the QMSR take effect?

On February 2, 2026, two years after the final rule was published. Until then, manufacturers had to comply with the QS regulation. On the same day, FDA stopped using the Quality System Inspection Technique (QSIT) and began inspecting under its updated compliance program for device manufacturers, Compliance Program 7382.850.

The changeover didn't reset the record history: FDA's QMSR FAQ says investigators may review quality system records created before February 2, 2026.

What changed from the old Quality System regulation?

The purpose and most obligations are similar. The framework, the vocabulary and some inspection rules changed:

TopicQS regulation (to Feb. 1, 2026)QMSR (from Feb. 2, 2026)
Core requirementsFDA-written sections, § 820.20 to § 820.250ISO 13485:2016 by reference, plus FDA additions
Record namesDMR, DHR, DHF, quality system recordISO 13485 terms: medical device file, device or batch record, design and development file
Management review, internal audit and supplier audit reportsExempt from FDA inspection (§ 820.180(c))Open to FDA review
Risk managementRisk analysis named mainly in design validationRequired in product realization by ISO 13485
Traceability for life-supporting devices§ 820.65ISO 13485 clause 7.5.9.2, through § 820.10(d)
InspectionsQSITCompliance Program 7382.850
DefinitionsFDA definitions in § 820.3ISO 13485 and ISO 9000 definitions; FD&C Act definitions prevail

Does the QMSR apply to PCBA and component suppliers?

Not directly. The scope section of the regulation says so in one sentence:

“The provisions of this part do not apply to manufacturers of components or parts of finished devices, but such manufacturers are encouraged to consider provisions of this regulation as appropriate.” (21 CFR 820.1(a)(2))

The QMSR defines a component as any “raw material, substance, piece, part, software, firmware, labeling, or assembly” intended to be included in the finished device, so a printed circuit board assembly built to a device maker's drawings is a component. The scope is unchanged from the QS regulation. In the final rule, FDA added three points:

  • FDA has legal authority to inspect component manufacturers under the FD&C Act should the need arise.
  • Leaving components out of the rule doesn't stop a device maker from requiring QMSR compliance by contract.
  • A device that has been made or assembled and needs only sterilizing, polishing, inspection and test, packaging or labeling is a finished device, not a component.

That last point marks the line. A supplier building boards that go into your device is a component manufacturer. A contractor that assembles the complete, working device is generally a manufacturer of a finished device, and the regulation's definition of manufacturer includes anyone who “assembles” one. Component manufacturers are also generally exempt from FDA establishment registration (21 CFR 807.65(a)).

What does the QMSR require device makers to do about suppliers?

Control them in proportion to risk, and keep the evidence. Purchasing now runs through ISO 13485 clause 7.4: evaluate and select suppliers on their ability to supply conforming product, set controls by the purchased product's effect on the device and the risk involved, monitor and re-evaluate suppliers, and keep records. In the final rule FDA calls this an “ongoing risk-informed assessment of suppliers,” and says:

  • device makers must document the type and extent of control they apply;
  • an appropriate mix of supplier and manufacturer controls is generally necessary;
  • where audits aren't practical, capability can be assessed through historical data, monitoring and trending, and inspection and testing;
  • certification may not give adequate assurance of supplier quality without further evaluation.

The practical change: under the old rule, supplier audit reports were exempt from FDA inspection. Under the QMSR, FDA can review management review, quality audit and supplier audit reports. Your audit of your PCBA supplier is now a record an investigator may read, so it should say what you checked and how findings were closed.

Which records should a device maker expect from its PCBA supplier?

The records your own batch record depends on. The QMSR drops the device history record (DHR) by name; FDA says its contents are now largely covered by the device or batch record in ISO 13485 clause 7.5.1. For a device built around circuit boards, that record leans on what the board supplier keeps and hands over:

  • Board serial numbers or lot codes, the work order and the document revisions built to.
  • Component lot or date codes, and the bare board lot.
  • Inspection and test results, and any nonconformances, deviations or rework, with approvals.
  • A certificate of conformance with each shipment.

Three QMSR points shape the detail:

  • Retention. ISO 13485 clause 4.2.5 requires records to be kept for at least the device lifetime the manufacturer defines, and not less than two years from release. Your supplier's retention should match.
  • UDI. § 820.35(c) requires the device maker to record the UDI for each device or batch. Supplier serial numbers and lot codes should link to it cleanly.
  • Life-supporting devices. § 820.10(d) applies ISO 13485 clause 7.5.9.2, written for implantables, to devices that support or sustain life. That clause calls for records of the components, materials and work environment conditions that could cause the device to miss its safety and performance requirements, which usually means component lot data from the board supplier.

What should you ask your PCBA supplier now that the QMSR is in effect?

  1. An ISO 13485:2016 certificate whose scope covers PCB assembly at the site building your boards. How to read and verify one.
  2. A signed quality agreement, with notice before parts, processes or build sites change.
  3. Traceability to the level your risk analysis needs, and a sample build record.
  4. Record retention that matches your device lifetime, and how quickly records can be pulled for an inspection or complaint investigation.
  5. Notification of nonconforming product, and your approval before any deviation or use-as-is decision.
  6. Process control evidence for soldering and test, and what triggers revalidation.
  7. Audit access on the schedule your risk assessment sets.

An FDA registration number usually isn't the right request for a board-only supplier, since component manufacturers are generally exempt from registration. And “QMSR certified” isn't a credential: FDA doesn't certify suppliers, and its inspections don't result in an ISO 13485 certificate. For the wider selection process, see Medical device contract manufacturing: choosing a PCBA partner.

Surface Art builds printed circuit board assemblies under an ISO 13485:2016 certificate from DQS Inc., scope “The contract manufacturing and testing of printed circuit board assemblies for the medical device industry,” with full lot traceability, AOI on every build and X-ray for hidden joints. To see how it would handle your boards, send your BOM and drawings.

What are common misconceptions about the QMSR?

  • “An ISO 13485 certificate means QMSR compliance.” No. FDA won't accept a certificate in place of an inspection, and the QMSR adds US requirements to ISO 13485, including UDI, complaint records, medical device reporting, corrections and removals, and labeling and packaging controls.
  • “Our suppliers must now comply with the QMSR.” Component and parts manufacturers are outside its scope. Your purchasing controls and quality agreement carry the requirements to them.
  • “The QMSR replaced MDSAP.” MDSAP remains a voluntary third-party audit program. FDA's own QMSR inspections don't follow the MDSAP audit plan.
  • “Records from before February 2026 no longer matter.” Investigators may review them.

This guide is general information about FDA's QMSR as published in 21 CFR Part 820 and FDA's guidance pages as of November 2026, not regulatory or legal advice. Confirm how it applies to your device with your regulatory and quality team.

Sources

  1. 21 CFR Part 820, Quality Management System Regulation (eCFR)
  2. 21 CFR 820.1, Scope (eCFR)
  3. Medical Devices; Quality System Regulation Amendments, final rule, 89 FR 7496 (Feb. 2, 2024)
  4. Medical Devices; Quality System Regulation Amendments; Correction, 89 FR 82945 (Oct. 15, 2024)
  5. FDA: Quality Management System Regulation (QMSR)
  6. FDA: Quality Management System Regulation, frequently asked questions
  7. 21 CFR 807.65, Exemptions for device establishments (eCFR)
  8. FDA: Who must register, list and pay the fee
  9. ISO 13485:2016, Medical devices: Quality management systems (ISO)